Skip to search formSkip to main contentSkip to account menu

Linagliptin

Known as: 1H-purine-2,6-dione, 8-((3r)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-, (R)-8-(3-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione, Linagliptin [Chemical/Ingredient] 
A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP… 
National Institutes of Health

Related topics

Related topics

25 relations
24 HR Linagliptin 5 MG / Metformin hydrochloride 1000 MG Extended Release Oral TabletDipeptidyl Peptidase 4 Inhibitors [MoA]In BloodIndigo Carmine

Narrower (3)

BI 1356GlyxambiTradjenta

Broader (3)

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsIncretins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Linagliptin-related pancreatitis in a diabetic patient with biliary calculus
Rationale: Dipeptidyl peptidase-4 inhibitors are commonly used drugs for the treatment of type 2 diabetes mellitus. While acute… 
2018
2018
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction
Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA-T2D), a… 
2016
2016
Synthesis and Biological Activity of Xanthene Derivatives as Antiasthamatic Agents
Plan: To develop some 1,3-dimethyl-7-[2-(piperazin-1-yl)acetyl]-2,3,6,7-tetrahydro-1H-purine-2,6-dione derivatives for their… 
2014
2014
Simultaneous Determination of Metformin, Sitagliptin, Saxagliptin, Linagliptin and Vildagliptin in Multicomponent Pharmaceutical Preparations by RP-HPLC
This paper describes the simple, economic, selective, and precise RP-HPLC method for the simultaneous determination of Metformin… 
2014
2014
Development and validation of ultraperformance liquid chromatography (UP-LC) method for estimation of a new anti-diabetic drug linagliptin in bulk and its tablet formulation
A simple, precise and accurate isocratic reversed-phase ultra performance liquid chromatography (UP-LC) method has been developed… 
2013
2013
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows
People with type 2 diabetes who take exenatide and sitagliptin have double the risk of hospitalisation for acute pancreatitis as… 
2013
2013
2.3 Cardiovascular (CV) Safety of Linagliptin in Patients with Type 2 Diabetes (T2D): A Pooled Comprehensive Analysis of Prospectively Adjudicated CV Events in Phase 3 Studies (376-OR)
SamenvattingIncidence of CV events is increased in T2D, but the potential for CV risk modulation with glucose lowering therapies… 
2013
2013
Comparison between the clinical efficacy of linagliptin and sitagliptin
After the introduction of dipeptidylpeptidase-4 (DPP-4) inhibitors into the treatment for diabetes, these drugs have been widely… 
2012
2012
DPP-4阻害薬リナグリプチン（トラゼンタ®）の薬理学的特性および臨床成績
リナグリプチン（トラゼンタ®）は，ジペプチジルペプチダーゼ-4（DPP-4）に対して選択性が高く，長時間持続性の強力なDPP-4阻害薬である．In vitro試験において，リナグリプチンは競合的であり，かつ可逆的にヒトDPP-4を阻害する．DPP-4… 
1981
1981
A double-blind, placebo-controlled evaluation of (dl)-3,7-dihydro-1,8-dimethyl-3-(2-methylbutyl)-1H-purine-2,6-dione in exercise-induced bronchospasm.
The investigational drug, (dl)-3, 7-dihydro-1, 8-dimethyl-3-(2-methylbutyl)-1 H-purine-2, 6-dione, has been proven to be an…